{"id":"corynebacterium-granulosum-p40","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a live attenuated strain of Corynebacterium granulosum designed to act as an immunological adjuvant. It works by triggering pattern recognition receptors on immune cells, promoting dendritic cell maturation and T-cell activation to enhance anti-tumor immunity. The mechanism leverages bacterial cell wall components to generate both innate inflammatory responses and adaptive immune memory against tumor-associated antigens.","oneSentence":"Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:51.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (specific indications in Phase 3 trials not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT00002455","phase":"PHASE3","title":"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma","status":"UNKNOWN","sponsor":"Centro Oncologico de Excelencia","startDate":"1971-04","conditions":"Breast Cancer, Colorectal Cancer, Melanoma (Skin)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Corynebacterium granulosum P40","genericName":"Corynebacterium granulosum P40","companyName":"Centro Oncologico de Excelencia","companyId":"centro-oncologico-de-excelencia","modality":"Biologic","firstApprovalDate":"","aiSummary":"Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity. Used for Cancer immunotherapy (specific indications in Phase 3 trials not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}